Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beroctocog alfa - GC Pharma

Drug Profile

Beroctocog alfa - GC Pharma

Alternative Names: GC 1101; GC 1101C; GC1101 D; GreenGene F; r-FVIII - GC Pharma; Recombinant factor VIII - GC Pharma

Latest Information Update: 01 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Green Cross
  • Developer GC Pharma
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Haemophilia A

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 22 Aug 2017 Beroctocog alfa is available for licensing as of 22 Aug 2017. http://www.greencross.com/eng/business/licensigout.do
  • 22 Aug 2017 Phase-III clinical trials in Haemophilia A in China (IV) before August 2017 (Green Cross pipeline, August 2017)
  • 01 Apr 2013 Phase-III clinical trials in Haemophilia A (In adolescents, In adults, In the elderly) in Canada, New Zealand, Poland, Russia and Ukraine (IV) after January 2013 (NCT01619046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top